G
Gilles Wandeler
Researcher at University of Bern
Publications - 180
Citations - 5530
Gilles Wandeler is an academic researcher from University of Bern. The author has contributed to research in topics: Medicine & Hepatitis B virus. The author has an hindex of 28, co-authored 139 publications receiving 4398 citations. Previous affiliations of Gilles Wandeler include Cheikh Anta Diop University.
Papers
More filters
Journal ArticleDOI
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.
Gilles Wandeler,Marion Schlauri,Marie-eve Jaquier,Janine Rohrbach,Karin J. Metzner,Jan Fehr,Juan Ambrosioni,Matthias Cavassini,Marcel Stöckle,Patrick Schmid,Enos Bernasconi,Olivia Keiser,Luisa Salazar-Vizcaya,Hansjakob Furrer,Andri Rauch +14 more
TL;DR: In this large cohort of HIV-infected patients with an incident HCV infection, treatment uptake and outcomes improved in recent years and the proportion of patients with a detectable HCV viral load decreased significantly with time.
Journal ArticleDOI
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Delphine Sculier,Gilles Wandeler,Sabine Yerly,Annalisa Marinosci,Marcel Stoeckle,Enos Bernasconi,Dominique L Braun,Pietro Vernazza,Matthias Cavassini,Marta Buzzi,Karin J. Metzner,Laurent A. Decosterd,Huldrych F. Günthard,Patrick Schmid,Andreas Limacher,Matthias Egger,Matthias Egger,Matthias Egger,Alexandra Calmy,Alexandra Calmy +19 more
TL;DR: DTG + FTC as maintenance therapy was non-inferior to cART in terms of efficacy, with a similar safety profile and a greater improvement in quality of life, thus expanding the offer of 2-drug simplification options among virologically suppressed individuals.
Journal ArticleDOI
Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies.
Antoine Jaquet,Marcellin Nouaman,Judicaël Tine,Aristophane Tanon,Camille Anoma,André Inwoley,Alain Attia,Didier K. Ekouevi,Moussa Seydi,François Dabis,Gilles Wandeler +10 more
TL;DR: While universal screening of hepatitis B virus is recommended in high burden countries, little is known about the proportion of HBV‐infected persons in need of antiviral therapy in these settings.
Journal ArticleDOI
Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa
Tiago Castro Lopes Azevedo,Marcel Zwahlen,Andri Rauch,Matthias Egger,Matthias Egger,Gilles Wandeler,Gilles Wandeler +6 more
TL;DR: Although hepatitis C virus screening is recommended for all HIV‐infected patients initiating antiretroviral therapy, data on epidemiologic characteristics of HCV infection in resource‐limited settings are scarce.
Journal ArticleDOI
HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling
Reneé de Waal,Richard J Lessells,Anthony Hauser,Roger D. Kouyos,Mary-Ann Davies,Matthias Egger,Matthias Egger,Gilles Wandeler +7 more
TL;DR: How mathematical modelling, combined with real-world data from the four African Regions of the International epidemiology Databases to Evaluate AIDS consortium, could provide an early warning system for HIV drug resistance in sub-Saharan Africa is described.